GlassScriptPhysician profile
Christopher M Ader
NPI 1508141235
$2,610.78
in general payments reported to CMS, 2019-2025
24 companies · $602 in 2025
The $602 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $378 · 2022: $471 · 2023: $663 · 2024: $497 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.82 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $972.28 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $274.83 | 2021-2023 | Brilinta, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $205.26 | 2025 | |
| Edwards Lifesciences Corporation | $160.26 | 2024 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $115.50 | 2022-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $103.47 | 2025 | Wegovy |
| Abiomed | $103.10 | 2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $95.18 | 2023-2025 | |
| Pfizer INC. | $72.34 | 2023-2025 | |
| Boston Scientific Corporation | $60.35 | 2024 | Watchman Flx |
| Amgen INC. | $47.52 | 2022-2024 | Repatha |
| Becton, Dickinson and Company | $40.14 | 2022 | |
| Irhythm Technologies, INC. | $35.44 | 2024 | Zio Monitor, Zio Xt Patch |
| Medtronic, INC. | $34.35 | 2024 | Micra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $32.17 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Cook Medical LLC | $30.90 | 2024-2025 | Evolution, Cook Celect |
| Merck Sharp & Dohme LLC | $22.15 | 2024 | Verquvo |
| Cordis US Corp. | $20.69 | 2025 | Mynx Control Venous |
| Astellas Pharma US INC | $20.09 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.97 | 2025 | Jardiance |
| Daiichi Sankyo INC. | $17.08 | 2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $16.71 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $15.60 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.